Developing Therapeutics for Alzheimer s Disease

Produk Detail:
  • Author : Michael S. Wolfe
  • Publisher : Academic Press
  • Pages : 676 pages
  • ISBN : 0128021640
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Developing Therapeutics for Alzheimer s Disease

Download or Read online Developing Therapeutics for Alzheimer s Disease full in PDF, ePub and kindle. this book written by Michael S. Wolfe and published by Academic Press which was released on 27 May 2016 with total page 676 pages. We cannot guarantee that Developing Therapeutics for Alzheimer s Disease book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics. Provides a realistic but promising assessment of the potential of various therapeutic approaches to Alzheimer’s disease Focuses primarily on neuroprotective agents and cognitive enhancers, as well as approaches to targeting the amyloid B-peptide, tau and Apolipoprotein E Discusses alternative approaches, preclinical and clinical development issues, related biomarkers and diagnostics, and prevention and nonpharmacological approaches

Developing Therapeutics for Alzheimer s Disease

Developing Therapeutics for Alzheimer s Disease
  • Author : Michael S. Wolfe
  • Publisher : Academic Press
  • Release : 27 May 2016
GET THIS BOOK Developing Therapeutics for Alzheimer s Disease

Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the

Pharmacological Mechanisms in Alzheimer s Therapeutics

Pharmacological Mechanisms in Alzheimer s Therapeutics
  • Author : A. Claudio Cuello
  • Publisher : Springer Science & Business Media
  • Release : 22 December 2007
GET THIS BOOK Pharmacological Mechanisms in Alzheimer s Therapeutics

The need for effective therapy to treat Alzheimer’s disease is greater than ever, but there is still no drug therapy that can stop or reverse the progression of the disease. There is, however, a great deal of anticipation over the imminent development of effective therapies as a result of the identification of promising targets for drug development. This book investigates these targets and examines ongoing strategies to develop effective therapies for this devastating neurodegenerative condition.

Amyloid Protein Precursor in Development Aging and Alzheimer s Disease

Amyloid Protein Precursor in Development  Aging and Alzheimer   s Disease
  • Author : C.L. Masters,K. Beyreuther,Marc Trillet
  • Publisher : Springer Science & Business Media
  • Release : 17 April 2013
GET THIS BOOK Amyloid Protein Precursor in Development Aging and Alzheimer s Disease

This book summarizes the last ten years' research on Alzheimer's disease. Genetic mutations in the gene which codes for amyloid precursor protein (APP) have now been shown to cause Alzheimer's disease in some families. Other genetic loci are now being discovered which relate to Alzheimer's disease in some families. Understanding the normal structure and function of the APP gene product will eventually provide avenues for developing specific therapeutic strategies targeted at the amyloid deposition in the Alzheimer's disease brain. Drugs

BACE

BACE
  • Author : Varghese John
  • Publisher : John Wiley & Sons
  • Release : 15 March 2010
GET THIS BOOK BACE

BACE inhibitors and their use in the treatment of Alzheimer's Disease BACE (β-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery. This book

Imaging in CNS Drug Discovery and Development

Imaging in CNS Drug Discovery and Development
  • Author : David Borsook,Lino R. Beccera,Edward Bullmore,Richard J. Hargreaves
  • Publisher : Springer Science & Business Media
  • Release : 10 March 2010
GET THIS BOOK Imaging in CNS Drug Discovery and Development

Drug development today needs to balance agility, speed, and risk in defining probability of success for molecules, mechanisms, and therapeutic concepts. New techniques such as fMRI promise to be part of a sequence that could transform drug development. Although numerous review articles exist that discuss the use of imaging in drug development, no one source is available that combines the various techniques and includes a discussion of disease mapping. Imaging in CNS Drug Discovery and Development, Implications for Disease and

Breakthrough Business Models

Breakthrough Business Models
  • Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation,Robert Giffin,Sally Robinson,Theresa Wizemann
  • Publisher : National Academies Press
  • Release : 17 March 2009
GET THIS BOOK Breakthrough Business Models

The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns. On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and

Alzheimer s Disease

Alzheimer s Disease
  • Author : Renee D. Wegrzyn,Alan S. Rudolph
  • Publisher : CRC Press
  • Release : 26 April 2012
GET THIS BOOK Alzheimer s Disease

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. With contributions from experts drawn from

Neurotherapeutics in the Era of Translational Medicine

Neurotherapeutics in the Era of Translational Medicine
  • Author : Richard A. Smith,Brian K. Kaspar,Clive N. Svendsen
  • Publisher : Academic Press
  • Release : 28 November 2020
GET THIS BOOK Neurotherapeutics in the Era of Translational Medicine

For the first time in history, there is now hope for treating neurological disorders that had previously been considered untreatable. The remarkable confluence of events that has heralded this is the focus of Neurotherapeutics in the Era of Translational Medicine. This anthology, written by many of the prominent scientists and researchers in the field of biotechnology, recounts the breathtaking advances that are revolutionizing treatment for disorders such as amyotrophic lateral sclerosis‎, spinal muscular atrophy, multiple sclerosis, Parkinson’s disease, myasthenia

Alzheimer s Disease Drug Development

Alzheimer s Disease Drug Development
  • Author : Jeffrey L. Cummings,Jefferson W. Kinney,Howard Fillit
  • Publisher : Unknown
  • Release : 25 September 2021
GET THIS BOOK Alzheimer s Disease Drug Development

"Alzheimer's Disease Drug Development: A Research and Development Ecosystem captures the complexity of Alzheimer's disease (AD) drug develop and provides a comprehensive set of perspectives from the many stakeholders involved in discovering and developing new therapies for AD. There is no greater unmet therapeutic need for humanity than effective therapies for brain disorders. The suffering caused by these conditions and other neurodegenerative disorders is overwhelming and is burdened with substantial stigma. Therefore, I have devoted my professional life to changing

Improving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders
  • Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
  • Publisher : National Academies Press
  • Release : 06 February 2014
GET THIS BOOK Improving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective

Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer s Disease
  • Author : Menghis Bairu,Michael Weiner
  • Publisher : Academic Press
  • Release : 28 August 2013
GET THIS BOOK Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in

Alzheimer s Disease

Alzheimer s Disease
  • Author : Harald Hampel,Maria C. Carrillo
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 25 September 2021
GET THIS BOOK Alzheimer s Disease

How current biomarkers are modernizing the diagnosis of Alzheimer's disease Expanding knowledge on genetic and epigenetic risk factors is rapidly enhancing our understanding of the complex molecular interactions and systems involved in the pathogenesis of Alzheimer's disease. In this publication, leading experts discuss emerging novel conceptual models of the disease along with advances in the development of surrogate markers that will not only improve the accuracy of diagnostic technologies but also improve the prospects of developing disease-modifying interventions. The novel

Design of Hybrid Molecules for Drug Development

Design of Hybrid Molecules for Drug Development
  • Author : Michael Decker
  • Publisher : Elsevier
  • Release : 05 April 2017
GET THIS BOOK Design of Hybrid Molecules for Drug Development

Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed. Drawing on practical case studies, the hybridization of